Bristol Myers Squibb: Hidden Gem or Value Trap? The Bull Case for 2025

Pharma giant Bristol Myers Squibb (BMY) is trading at a crossroads—cheap valuation meets pipeline risks. Here's why Wall Street might be underestimating this biotech behemoth.

The Upside Case: Deep Value Play

BMY's P/E ratio sits at basement levels compared to flashier mRNA rivals. Their dividend yield? A juicy 4.2%—almost too good for a blue-chip pharma stock (which probably means the market knows something we don't).

Pipeline Problems or Patent Cliff Overblown?

Yes, Eliquis goes generic in 2026. But Opdivo's new combo therapies could steal KEYTRUDA's lunch—if the FDA plays ball. Their $14B Celgene acquisition finally stopped bleeding cash last quarter.

The Cynic's Take

Another 'value' stock where 'value' means 'no growth prospects.' But in this market? A 4% yield that might actually get paid is practically a stablecoin.

Bottom line: BMY won't moon like crypto—but for recession-proof exposure, it's got more legs than most pharma dinosaurs.